These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Pattern and associated factors of anti-hepatitis C virus treatment-induced adverse reactions.
    Author: Ravi S, Nasiri-Toosi M, Karimzadeh I, Khalili H, Ahadi-Barzoki M, Dashti-Khavidaki S.
    Journal: Expert Opin Drug Saf; 2014 Mar; 13(3):277-86. PubMed ID: 24386997.
    Abstract:
    OBJECTIVES: To assess the pattern and possible risk factors of conventional and/or pegylated interferon alpha (IFN-α) plus ribavirin therapy for causing adverse reactions in patients with chronic hepatitis C virus. Patients attending a referral center in Iran were assessed. METHODS: During an 18 month period all adult individuals diagnosed with chronic hepatitis C virus who planned to receive anti-hepatitis C virus treatment were prospectively screened regarding all related subjective and objective adverse drug reactions. RESULTS: The number of adverse drug reactions were significantly associated with the number of concomitant medications (p < 0.001), female gender (p = 0.027), increased age (p = 0.001), pegylated IFN-α (p = 0.015) and hepatitis C virus genotype 1 (p = 0.002). History of a prior anti-hepatitis C virus treatment course (OR = 3.081, 95% CI = 1.174 - 6.085; p = 0.022) and the number of co-administered medications (OR = 1.165, 95% CI = 1.034 - 1.314; p = 0.012) were identified as the only statistically significant risk factors for developing anti-hepatitis C virus medication-related psychiatric and dermatologic adverse reactions, respectively. CONCLUSION: These data could be exploited by health-care professionals and policy makers as a guide for developing optimal educational and preventive strategies in the setting of anti-hepatitis C virus medication safety.
    [Abstract] [Full Text] [Related] [New Search]